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There are currently very few English reports about Japanese pediatric human immunodeﬁciency virus
(HIV). In this study, we introduce our experience with pediatric HIV in a single hospital, and review the
present status of HIV infections in children in Japan.
In Japan, the main infection routes of HIV include sexual activity, mother-to-child transmission
(MTCT), blood or blood product transfusion, and drug use. Most pediatric HIV patients have been infected
by MTCT in recent years. One survey showed that in Japan, 52 babies were infected by MTCT between
1984 and 2011. Only 2 cases of pediatric HIV infection have been reported since 2010. The MTCT rate has
decreased to 0.5% owing to several preventive interventions. In addition, the HIV antibody test is now
performed in more than 98.3% of pregnant women in Japan.
© 2014, Japanese Society of Chemotherapy and The Japanese Association for Infectious Diseases.
Published by Elsevier Ltd. All rights reserved.1. Introduction
Pediatric acquired immunodeﬁciency syndrome (AIDS) is
caused by infection of the human immunodeﬁciency virus (HIV),
which is a single-stranded, positive-strand RNA virus with an en-
velope, belonging to the lentivirus genus of the Retroviridae family
that has reverse transcriptase activity. The virus is classiﬁed into 2
types: HIV-1 and HIV-2. Both viruses were isolated from AIDS pa-
tients and identiﬁed in the 1980s by Luc Montagnier of the Pasteur
Institute. Positive cases for HIV-2 are extremely rare in Japan,
whereas HIV-1 infections have recently been a major problem.
There are currently very few English reports about Japanese pedi-
atric HIV. In this study, we introduce our experience with pediatric
HIV in a single hospital, and review the present status of HIV in-
fections in children in Japan.2. The latest pediatric case of AIDS in our department
The patient was diagnosed as having hemophilia B at 2 months
of age because of his bleeding tendency, and he thereafter received
blood product transfusions irregularly. HIV antibody positivity was
found at the age of 6 in 1988. He was susceptible to infections: þ81 3 3344 0643.
shima).
d The Japanese Association for Infectiowing to his low CD4þ count since 8 years of age. CMV, HSV, EBV,
and HCV antibody positivity and HCV 50 RNA-PCR positivity were
also conﬁrmed. The patient died as a result of acute respiratory
infection at the age of 13 in 1995. Liver autopsy showed cirrhosis
owing to chronic hepatitis. The histopathological ﬁndings of the
liver were ﬁbrosis with marked lipid droplets, bridging ﬁbrosis,
central ﬁbrosis, disturbance of the liver cell cord, inﬁltration of
lymphocytic cells in the portal area, and cholangitis (Fig. 1).
Liver cirrhosis developed in this patient at 3 years after testing
positive for HCV 50 RNA-PCR, as a result of severe chronic hepatitis
that may have lasted for a maximum of 12 years, since HCV infec-
tion in this patient may have actually occurred at a very young age
by blood product transfusion. From the fact that he had no or very
few CD4þ cells, it is thought that the liver cell damage caused by
cytotoxic T lymphocyte CD8þ cells or other cells led to hepatitis and
liver cirrhosis.
The course of this patient was consistent with a study of adults
showing that the progression of HCV hepatitis was accelerated by
the co-infection of HIV and HCV [1]. HIV and HCV co-infected pa-
tients showed a higher rate of cholangitis than patients with HIV
infection alone.
It was reported that HIV infections accelerate liver ﬁbrosis
caused by HCV, and that low levels of CD4 are correlated with liver
ﬁbrosis [2]. A study of the natural history of hemophilic patients
infected with HCV showed early liver-associated death in the HIV-
co-infected patients [3]. HCV-speciﬁc CD8þ cell responses areous Diseases. Published by Elsevier Ltd. All rights reserved.
Fig. 1. Histopathological examination of a liver sample obtained from an HIV-1-infected child. Left: hematoxylin and eosin staining; Right: azan staining.
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co-infected with HIV [4].
3. Current status in our department
To date, we have experiencedmore than 10 deliveries fromHIV-
positive patients. We could not collect the precise proﬁles of pa-
tients before 2003; however, we were able to obtain data of 9 de-
liveries (6 boys and 3 girls) from HIV-1 carrier mothers between
2003 and 2014. None of these babies were infected with HIV, owing
to preventive measures such as intravenous AZT [azidothymidine,
also known as zidovudine (ZDV) or Retrovir] for mothers and oral
AZT for babies (Table 1). All deliveries were performed by selective
cesarean section. The birth weights of these babies were from
1772 g to 3228 g. One out of the 9 babies was small-for-date. Five
needed oxygen for 1e5 days. Two showed transient hypoglycemia.
According to Tubiana et al. [5], in the French Perinatal Cohort,
there were no differences between 19 patients (transmitters) and
60 control subjects (nontransmitters) in geographical origin,
gestational age at HIV diagnosis, type of antiretroviral therapy
(ART) received, or elective cesarean delivery. Viral load (less than
500 copies/mL) was the only factor independently associated withTable 1
Proﬁle of subjects treated with preventive regimens.
Birth Sex Birth
weight (g)
Gestation Apgar
score****
Mode of
delivery
Condition of mother
CD4þ count Viral load
(copies/m
1* 2003 m 2960 37 9(1), 9(5) Selective
cesarean
806 <50
2* 2005 m 2265 37 9(1) Selective
cesarean
926 <50
3** 2006 m 2845 36 7(1) Selective
cesarean
410 Not done
4 2007 m 2605 37 8(1) Selective
cesarean
322 61
5*** 2008 m 3228 37 8(1) Selective
cesarean
534 Not done
6*** 2012 f 3110 37 9(1), 10(5) Selective
cesarean
369 <20
7 2012 f 1772 37 8(1), 9(5) Selective
cesarean
478 Not done
8 2012 f 2246 36 7(1), 8(5) Selective
cesarean
520 <20
9** 2013 m 2784 37 8(1), 9(5) Selective
cesarean
567 Not done
*, **, ***: siblings.
3TC: lamivudine; NFV: nelﬁnavir mesylate; ATV: atazanavir; LPV: lopinavir; RTV: ritona
TTN: transient tachypnea of the newborn, SGA: small for gestational age.
****: 1-min (1) and 5-min (5) Apgar scores are shown.mother-to-child transmission (MTCT) of HIV. Viral loads of all
mothers in this study were less than 61 copies/mL.
4. Epidemiology and infection route of pediatric HIV
infection
In Japan, the main infection routes of HIV include sexual activity
(including abuse), MTCT, blood or blood product transfusion, and
drug use. Infection by blood transfusion from an infected donor was
reported in 2 cases in 2013, but occurs only very rarely nowadays, in
cases in which the donor was in an early window period after
infection [6].
Although a quarter century has passed since the discovery of
HIV, no effective vaccine has been developed to date. In 2011, the
number of patients infected with HIV worldwide was estimated to
be 33.4 million (2.1 million under the age of 5 years). Owing to the
availability of effective antiviral treatments, the virus is now
considerably under control. However, 2 million people (280,000
under the age of 5 years) still die of AIDS every year [7].
Thenumberof newly infectedpeople in Japan is rapidly increasing,
which is unlike that in other developed countries. At present, one-
fourth of these newly infected patients are Japanese (Fig. 2) [7].Treatments Condition of baby HIV-RNA
L)
Mother Baby
AZT/3TC/NFV ZDV syrup 8 mg/kg/d
for 6 weeks
TTN O2 for 2 days (-) at
6 months
ZDV/3TC/ATV ZDV syrup 8 mg/kg/d
for 6 weeks
TTN O2 for 3 days (-) at
6 months
AZT/3TC/NFV ZDV syrup 8 mg/kg/d
for 6 weeks
TTN O2 for 5 days,
hypoglycemia
(-) at
1 month
AZT/3TC/NFV ZDV syrup 8 mg/kg/d
for 6 weeks
Normal (-) at
6 months
AZT/3TC ZDV syrup 8 mg/kg/d
for 6 weeks
Normal (-) at
4 months
AZT/3TC/LPV þ RTV ZDV syrup 8 mg/kg/d
for 6 weeks
Normal (-) at
3 months
TDF þ FTC/LPV þ RTV ZDV syrup 8 mg/kg/d
for 6 weeks
Hypoglycemia, SGA,
hyperbilirubinemia,
suspicion of hearing
defect
(-) at
4 months
TDF þ FTC/ATV/RTV ZDV syrup 8 mg/kg/d
for 6 weeks
TTN O2 for 4 days (-) at
3 months
AZT/3TC/LPV þ RTV ZDV syrup 8 mg/kg/d
for 6 weeks
TTN O2 for 1 day (-) at
4 months
vir; FTC: emtricitabine.
Fig. 2. Nationality of new HIV patients who were infected by MTCT in Japan (from Ref. [7]).
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recent years. One survey showed that in Japan, 52 babies were
infected byMTCT between 1984 and 2011 [6]. Cases of HIV infection
by MTCT were reported every year from 1984 to 2000. Most
infected babies were born by vaginal delivery. After 2000, a total of
only 4 babies were infected (in 2002, 2006, 2008, and 2010). These
babies were born by vaginal delivery without ART because the HIV
status of the mother was unknown before delivery. The infection
rates in Japan of babies of HIV carrier mothers, who were born by
selective cesarean, emergency cesarean, and vaginal delivery were
0.7%, 2.5%, and 25.8%, respectively. Selective cesarean was per-
formed in 89.5% of these cases [7]. Only 2 cases of pediatric HIV
infection have been reported since 2010 (Fig. 3). One infected baby
was born to a mother who did not take adequate preventive
measures [8].Fig. 3. Number of MThe MTCT rate has decreased to 0.5% owing to several preven-
tive interventions [6]. In addition, the HIV antibody test is now
performed in more than 98.3% of pregnant women in Japan [6]. The
prognosis of HIV infection has drastically improved with effective
early treatment and management.
5. Clinical symptoms in HIV-1 infected children
In adults, transient symptoms similar to infectious mono-
nucleosis or ﬂu (fever, lymphadenopathy, muscle pain, diarrhea,
etc.) appear approximately 2e4 weeks after the primary infection
in 40%e90% of adults. Infected adults subsequently enter an
asymptomatic phase of several years. During this time, the HIV
virus multiplies and the destruction of CD4þ T cells occurs. When
the number of CD4þ T cells is reduced to less than 200/mm3 or 15%,TCTs in Japan.
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with various opportunistic infections.
AIDS is diagnosed at the time of appearance of an AIDS-deﬁning
disease, as stated in the Center for Diseases Control and Prevention
clinical categories of HIV in children [9].
Infection after puberty is almost identical to that of adults. MTCT
has the clinical features shown in Table 2. The characteristics of HIV-
infected children are as follows [10,11]: the clinical latency period is
shorter and progression is signiﬁcantly faster than that of adults.
Primary opportunistic infections are often seen in children, whereas
a reactivation of latentmicroorganisms is common in adults. Besides
opportunistic infections, severe and recurrent common pneumo-
coccal infections (pneumonia, otitis media, sepsis, meningitis, etc.)
often occur at the onset of AIDS in children. Nervous system ab-
normalities and effects on general growth also occur.
6. Diagnosis
Tests for the diagnosis of HIV infections are usually performed
by serological assays such as the enzyme immunoassay in pregnant
women and children. Because the serological assay can result in
false positivity, the results must be conﬁrmed by Western blotting.
Diagnostic tests are recommended in sexually active patients who
have an inﬂuenza-like illness or infectious mononucleosis-like
symptoms, as well as those with opportunistic infections such as
herpes zoster and oral candidiasis. The window period (6 weeks
from the time of infection) must also be considered. Although HIV-
2 infection is rare in Japan, the screening test is also useful for
detecting HIV-2 infections.
Because there is a possibility of false positivity due to maternal
antibodies in cases of MTCT, serological assays are not suitable for
diagnosis until the child is 18 months of age. If an infant is more
than 6 months of age, MTCT can be ruled out if the presence of
antibodies is negative in 2 tests performed more than 1 month
apart, and if there is no sign of infection. After giving birth, diag-
nosis of the carrier mother is usually performed using PCR. At 4
time points, namely, 48 h, 14e21 days, 1e2 months, and 4e6
months after delivery, PCR analysis is performed, and if the results
are positive, they are conﬁrmed by a second PCR analysis [12].
In infected babies, the plasma viral load is measured by
quantitative HIV-1 RNA-PCR and CD4þ T-cell counts that are
measured monthly before 12 months of age and every 3 months
after 1 year of age. The CD4þ T cell count represents the level of
progression whereas the plasma RNA level represents the speed
of progression [13].Table 2
Differences between infants and adolescents infected with HIV [11].
Infants
Main infection route MTCT
Clinical incubation period Several months to several years
Type of immunodeﬁciency Cellular immunity ¼ humoral immunity
Type of opportunistic infection Primary > reactivation and reinfection
Common opportunistic infections
and opportunistic tumors
Those listed in the right column, as well a
pneumococcal infection, severe chicken po
severe measles, lymphocytic interstitial
pneumonia (EBV), etc.
Cautions regarding diagnosis Serological diagnosis cannot be used beca
of transplacental antibodies
ART Special caution is required for age-speciﬁc
effects and long-term effects. There are fe
conﬁrmed to be both valid and safe, and d
forms are limited.
Prevention ART (mother and child), elective cesarean,7. Management of at-risk babies
Children are infected at a high rate (more than 25%) from
carrier pregnant mothers who do not take adequate precautions,
and therefore, the prevention of MTCT is very important [14].
The 4 major key points for the prevention of MTCT are the
following. First, reducing maternal viral load by ART. Second,
avoiding exposure to maternal blood upon vaginal delivery or
during selective cesarean section. Third, eliminating HIV in the
child by ART. Fourth, refraining from breast feeding to prevent
infection through breast milk. Oral administration of ZDV
(600 mg/day) or multiple drug combination therapy (highly
active ART: HAART) is recommended in pregnant women after 14
weeks of gestation. Additionally, Retrovir should be administered
intravenously during the entire period of labor [15]. For new-
borns, ZDV should be administered as an oral syrup (8 mg/kg/
day, 4 qds) or intravenously (1.5 mg/kg every 6 h) until 6 weeks
after birth. If strong side effects such as agranulocytosis, anemia,
or vomiting occur, the duration of the treatment should be
reduced to 4 weeks. In premature infants born before 35 weeks
of gestation, ZDV should be administered at the above doses, but
only 2 times a day until 2 weeks after birth and 3 times a day
thereafter [7,15].
In addition, mitochondrial disorders of the newborn and future
fatal lactic acidosis, as well as HELLP syndrome in pregnant women
[16] should be taken into account.
Other preventive measures are maintaining mothers' blood HIV
RNA level below the detection limit and maintaining immune
function for as long as possible. For this purpose, ART and pre-
ventive treatments for opportunistic malignancies and infections
are performed [17].
ART is usually performed as a combination therapy of more
than 3 drugs (HAART) [17]. The selection of anti-HIV drugs and the
timing of the initiation of treatment are particularly important.
ART for children is limited to only 3 types of drugs: nucleoside
reverse transcriptase inhibitors (NRTIs), non-nucleoside reverse
transcriptase inhibitors (NNRTIs), and protease inhibitors (PIs).
The use of other new drugs for children is limited because of their
restrictions for use and the dosage forms required. A combination
of 1 PI and 2 NNRTIs can be administered to children. The NNRTI of
ﬁrst choice is efavirenz (EFV), because of its high efﬁcacy and its
availability as capsules. Nevirapine (NVP) syrup can also be used in
children; however, it has side effects of severe rash and liver
dysfunction. After puberty, the treatment for HIV is the same as in
adults.Adolescents
Sexual transmission
Several years to several tens of years
Cellular immunity > humoral immunity
Reactivation and reinfection > primary
s
x,
Pneumocystis pneumonia, CMV retinitis,
herpes zoster, malignant lymphoma (EBV),
tuberculosis, MAC (Mycobacterium avium complex),
cryptococcosis, Kaposi sarcoma, etc.
use Since there are many false-positive cases, veriﬁcation
tests (Western blotting) are required for positive cases.
False-negative results during the window period should
also be considered.
side
w drugs
osage
Fundamentally same as adults
bottle feeding Sex education
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Points that require special attention in HIV treatment are
multidrug interactions and side effects of individual drugs. HIV RNA
levels and CD4þ cell counts must be measured regularly to estimate
the efﬁcacy of the drug and to detect drug resistance. In addition,
side effects of and adherence to the treatment should bemonitored.
PIs and NNRTIs aremetabolized by liver cytochrome P450 (CYP).
Attention must be paid to their interaction with other drugs and
herbs that are also metabolized by CYP [18].
Immune reconstitution syndrome (opportunistic malignancies
and opportunistic infections causing recurrence and re-
exacerbation) might occur when ART is initiated after the onset
of immunodeﬁciency [19]. It is caused by an induction of the sup-
pressed immune response or inﬂammatory response.
Anti-HIV drugs that are administered during pregnancy or to
neonates have been associated with mitochondrial toxicity in ne-
onates. Two deaths in Europe due to mitochondrial dysfunction in
HIV-uninfected infants that were born to infected mothers who
were treated with anti-HIV drugs during pregnancy were reported
[20,21]. Therefore, we should be concerned about the subsequent
onset of neuromuscular diseases among children who receive an-
tiretroviral drugs, particularly during the neonatal period.
9. Concluding remarks
For the care of HIV-infected children and children born from
infectedmothers, special supervision of vaccination and prevention
of transmission are required, as well as lifelong psychological and
physical support.
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